Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?

被引：33
|
作者：
Kosmider, Olivier [1 ]
Passet, Marie [1 ]
Santini, Valeria [2 ]
Platzbecker, Uwe [3 ]
Andrieu, Valerie [4 ]
Zini, Gina [5 ]
Beyne-Rauzy, Odile [6 ]
Guerci, Agnes [7 ]
Masala, Erico [8 ]
Balleari, Enrico [9 ]
Bulycheva, Ekaterina [3 ]
Dreyfus, Francois [10 ]
Fenaux, Pierre [11 ]
Fontenay, Michaela [1 ]
Park, Sophie [12 ]
机构：
[1] Hop Cochin, AP HP, Hematol Biol, Paris, France
[2] Univ Florence, AOU Careggi, Hematol, I-50121 Florence, Italy
[3] Univ Hosp Carl Gustav Dresden, Dresden, Germany
[4] Hop Bichat Claude Bernard, AP HP, Hematol Biol, Paris, France
[5] Univ Cattolica Sacro Cuore, Rome, Italy
[6] Oncopole, IUCT, Toulouse, France
[7] Hop Brabois, Nancy, France
[8] Univ Florence, Florence, Italy
[9] IRCCS AOU San Martino IST Genova, Genoa, Italy
[10] Hop Cochin, Serv Hematol, Paris, France
[11] Hop St Louis, Serv Hematol Seniors, Paris, France
[12] Univ Grenoble Alpes, CHU Grenoble Alpes, Clin Univ Hematol, Grenoble, France
来源：
HAEMATOLOGICA | 2016年 / 101卷 / 07期
关键词：
myelodysplastic syndromes; cytogenetics and molecular genetics; red cells; SURVIVAL; IMPACT; MODEL;
D O I：
10.3324/haematol.2016.142695
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：280 / 283
页数：4
相关论文
共 50 条
  • [31] Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial
    van de Loosdrecht, A. A.
    Cremers, E. M. P.
    Alhan, C.
    Duetz, C.
    In 't Hout, F. E. M.
    Visser-Wisselaar, H. A.
    Chitu, D. A.
    Verbrugge, A.
    Cunha, S. M.
    Ossenkoppele, G. J.
    Janssen, J. J. W. M.
    Klein, S. K.
    Vellenga, E.
    Huls, G. A.
    Muus, P.
    Langemeijer, S. M. C.
    de Greef, G. E.
    te Boekhorst, P. A. W.
    Raaijmakers, M. H. G.
    van Marwijk Kooy, M.
    Legdeur, M. C.
    Wegman, J. J.
    Deenik, W.
    de Weerdt, O.
    van Maanen-Lamme, T. M.
    Jobse, P.
    van Kampen, R. J. W.
    Beeker, A.
    Wijermans, P. W.
    Biemond, B. J.
    Tanis, B. C.
    van Esser, J. W. J.
    Schaar, C. G.
    Noordzij-Nooteboom, H. S.
    Jacobs, E. M. G.
    de Graaf, A. O.
    Jongen-Lavrencic, M.
    Stevens-Kroef, M. J. P. L.
    Westers, T. M.
    Jansen, J. H.
    LEUKEMIA, 2024, 38 (04) : 840 - 850
  • [32] Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial
    A. A. van de Loosdrecht
    E. M. P. Cremers
    C. Alhan
    C. Duetz
    F. E. M. in ’t Hout
    H. A. Visser-Wisselaar
    D. A. Chitu
    A. Verbrugge
    S. M. Cunha
    G. J. Ossenkoppele
    J. J. W. M. Janssen
    S. K. Klein
    E. Vellenga
    G. A. Huls
    P. Muus
    S. M. C. Langemeijer
    G. E. de Greef
    P. A. W. te Boekhorst
    M. H. G. Raaijmakers
    M. van Marwijk Kooy
    M. C. Legdeur
    J. J. Wegman
    W. Deenik
    O. de Weerdt
    T. M. van Maanen-Lamme
    P. Jobse
    R. J. W. van Kampen
    A. Beeker
    P. W. Wijermans
    B. J. Biemond
    B. C. Tanis
    J. W. J. van Esser
    C. G. Schaar
    H. S. Noordzij-Nooteboom
    E. M. G. Jacobs
    A. O. de Graaf
    M. Jongen-Lavrencic
    M. J. P. L. Stevens-Kroef
    T. M. Westers
    J. H. Jansen
    Leukemia, 2024, 38 : 840 - 850
  • [33] Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?
    Itzykson, R.
    Thepot, S.
    Beyne-Rauzy, O.
    Ame, S.
    Isnard, F.
    Dreyfus, F.
    Salanoubat, C.
    Taksin, A. L.
    Chelgoum, Y.
    Berthon, C.
    Malfuson, J. V.
    Legros, L.
    Vey, N.
    Turlure, P.
    Gardin, C.
    Boehrer, S.
    Ades, L.
    Fenaux, P.
    LEUKEMIA RESEARCH, 2012, 36 (04) : 397 - 400
  • [34] A Systematic Literature Review of Predictors of Erythropoiesis-Stimulating Agent Failure in Lower-Risk Myelodysplastic Syndromes
    Boccia, Ralph
    Xiao, Hong
    von Wilamowitz-Moellendorff, Caroline
    Raorane, Renuka
    Deshpande, Sohan
    Klijn, Sven L.
    Yucel, Aylin
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (09)
  • [35] Lower-Risk Myelodysplastic Syndromes: Erythropoiesis-Stimulating Agent Treatment Approaches and Outcomes in the United States
    Savill, Kristin M. Zimmerman
    Gajra, Ajeet
    Price, Kwanza
    Kish, Jonathan K.
    Brown-Bickerstaff, Cherrishe
    Falkenstein, Angelica
    Miller, Talia
    Laney, JaLyna
    Mukherjee, Sudipto
    BLOOD, 2021, 138
  • [36] Predictors of Erythropoiesis-Stimulating Agent Failure in Lower-Risk Myelodysplastic Syndromes: Systematic Literature Review
    Boccia, Ralph, V
    Deshpande, Sohan
    Von Wilamowitz-Moellendorff, Caroline
    Raorane, Renuka
    Klijn, Sven L.
    Xiao, Hong
    Yucel, Aylin
    BLOOD, 2022, 140 : 12355 - 12356
  • [37] Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis
    Victor Moyo
    Patrick Lefebvre
    Mei Sheng Duh
    Behin Yektashenas
    Suneel Mundle
    Annals of Hematology, 2008, 87 : 527 - 536
  • [38] Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis
    Moyo, Victor
    Lefebvre, Patrick
    Duh, Mei Sheng
    Yektashenas, Behin
    Mundle, Suneel
    ANNALS OF HEMATOLOGY, 2008, 87 (07) : 527 - 536
  • [39] MANAGEMENT OF MYELODYSPLASTIC SYNDROMES WITH ERYTHROPOIESIS STIMULATING AGENTS (ESAS): A REAL-LIFE EXPERIENCE
    Cerchione, C.
    Vitagliano, O.
    Pareto, A. E.
    Di Perna, M.
    Cerciello, G.
    Soriente, I.
    Alfinito, F.
    Pane, F.
    HAEMATOLOGICA, 2016, 101 : 840 - 840
  • [40] Drug utilization and cost considerations of erythropoiesis-stimulating agents in patients with myelodysplastic syndromes
    Lalibert, Francois
    McKenzie, Scott R.
    Bookhart, Brahim K.
    Duh, Mei S.
    Lefebvre, Patrick
    BLOOD, 2007, 110 (11) : 225B - 225B
12345